Optimizing Y90 Therapy for Radiation Lobectomy

STATUS

Recruiting
End date

Jun 5, 2025
participants needed

104
sponsor

Northwestern University

Send

Updated on 19 February 2024

See if I qualify

angiography

cirrhosis

liver disease

hepatectomy

radioembolization

liver diseases

Summary

HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.

Description

In this study there will be 2 different patient groups 1 and 2 that will consist of 40 and 64 patients, respectively with hepatocellular carcinoma who are eligible for resection and to receive Y90 radioembolization who have inadequate future liver remnant.

Y90 radioembolization uses radioactive beads (microspheres), which are tiny glass particles that are loaded with radiation. The beads are injected into an artery of the liver that supplies blood to the tumor(s). The beads flow to the tumor(s) and become trapped inside. The beads release the Y90 radiation inside the tumor(s).

Liver resection is used to remove the part of the liver that has the HCC tumor(s). It has been shown that Y90 radioembolization can also increase the untreated liver's size and volume. Patients with HCC may be liver resection candidates if they have a large enough liver.

The purpose of this research is to determine if there is an ideal Y90 dose to increase liver volume of the future liver remnant. This research may help determine the best Y90 dose for future patients who need a larger liver to have a liver resection.

Participants in Group 1 will have standard-of-care Y90 radioembolization as well as study-specific optional liver biopsy.

Participants who already have a planned Y90 radioembolization treatment with the dose range established in Group 1 will be enrolled into Group 2. Patient Group 2 will have blood drawn and a quantitative MRI performed at specific timepoints.

The study will last up to 3 months. Participants' health status will be followed up to 5 years.

Details

Condition	Metastasis, Brain Metastases, Liver Metastases, neoplasm metastasis, Graft, Transplantation, HEPATOCELLULAR CARCINOMA, Brain Metastases, Liver Metastases, neoplasm metastasis, Resection, Adult Primary Liver Cancer
Age	18years - 100years
Treatment	Y90 radioembolization
Clinical Study Identifier	NCT04390724
Sponsor	Northwestern University
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Patients must have been diagnosed with HCC confirmed by histology or must meet one of the following American Association for the Study of Liver Diseases (AASLD) guidelines
	AFP >200 and radiological evidence (arterial hypervascularity) of lesion > 2 cm does not require biopsy
	Two imaging modalities (triphasic CT, MRI, ultrasound, angiography) demonstrating arterial hypervascularity in the background of cirrhosis does not require biopsy
	One imaging modality with a lesion with arterial hypervascularity with wash out in early or delayed venous phase, does not require a biopsy
	Child-Pugh stage A
	Future Liver Remnant (FLR) of < 40%
	ECOG Performance Status 0-1
	Bilirubin 3.0 mg/dl- Treatment may proceed if the Bilirubin is elevated if the tumor may be isolated from a vascular standpoint
	Creatinine 2.0 mg/dl
	ANC 1.5 K/uL
	Platelets > 25 K/uL
	Patient is willing participate in this study and has signed the consent
	For Group 2 patients only
	Patients planned Y90 dose and embolic load is found to fall within the optimal dose and embolic load size from data from Group 1 patients
Exclusion Criteria
	Patient must not be pregnant
	NOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone
	a tubal ligation, or remaining celibate by choice) who meets the following
	criteria
	Has not undergone a hysterectomy or bilateral oophorectomy
	Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for > 12 months) 2\. For Patients in Group 2 only
	Patients who have contraindications to MRI
	Patients that are claustrophobic and haven't been able to tolerate an MRI in the past. (Patients with mild claustrophobia are eligible and have the option to take
	mg oral Lorazepam prior to the MRI, if needed)
	Allergy to gadolinium-containing contrast media
	Patients with a pacemaker, metallic clip, aneurysm clips, shrapnel fragments, etc
	Patients with an eGFR < 30 mL/min/m 3\. Must not have any significant life-threatening extra-hepatic disease or lifethreatening secondary malignancies, including patients who are on dialysis, have unresolved diarrhea, have serious unresolved infections including patients who are known to be HIV positive or have acute HBV or HCV 4\. Must not have any contraindications to angiography and selective visceral catheterization such as bleeding diathesis or coagulopathy that is not correctable by usual therapy of hemostatic agents (e.g. closure device) 5\. Must not have any co-morbid disease or condition that would place the patient at undue risk and preclude safe use of TheraSphere treatment, in the Investigator's judgment 6\. History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Optimizing Y90 Therapy for Radiation Lobectomy